Significance of pharmacist intervention to oral antithrombotic therapy in the pharmaceutical outpatient clinic of cardiovascular internal medicine: a retrospective cohort study

Table 3 Logistic regression analysis according to Bleeding Academic Research Consortium bleeding greater than type 2

	Univariate analysis		Multivariate analysis
	OR (95% CI)	P-values	OR (95% CI)	P-values
Elderly (> 65 years old)^a	2.57 (1.30–5.07)	0.006	2.29 (1.13–4.65)	0.022
Male	0.89 (0.54–1.46)	0.65
SCr (> 2.26 mg/dL)^a	1.01 (0.20–5.11)	0.99
eGFR (< 60 mL/min/1.73m²)	1.68 (1.04–2.70)	0.034	1.44 (0.87–2.37)	0.16
Liver function^a (AST > 90 IU/L or ALT > 69 IU/L)	0.50 (0.06–4.22)	0.53	0.78 (0.09–6.80)	0.82
More than two antithrombotic drugs^a	0.99 (0.52–1.90)	0.97	0.94 (0.48–1.84)	0.86
Pharmacist intervention	0.53 (0.32–0.90)	0.018	0.51 (0.30–0.87)	0.014

Elderly, each laboratory test value, and the number of antithrombotic drugs were the baseline values at the start of observation
OR Odds ratio, CI Confidence interval, SCr Serum creatinine value, eGFR Estimated glomerular filtration rate, AST Aspartate aminotransferase, ALT Alanine aminotransferase
^aRisk factors included in HAS-BLED (Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage) score

ISSN: 2055-0294